{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T02:14:17Z","timestamp":1782267257597,"version":"3.54.5"},"reference-count":96,"publisher":"Georg Thieme Verlag KG","issue":"03","license":[{"start":{"date-parts":[[2023,7,20]],"date-time":"2023-07-20T00:00:00Z","timestamp":1689811200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Semin Liver Dis"],"published-print":{"date-parts":[[2023,8]]},"abstract":"<jats:p>First discovered over 40 years ago, the hepatitis delta virus (HDV) is a unique RNA virus, requiring hepatitis B virus (HBV) antigens for its assembly, replication, and transmission. HBV and HDV can be acquired at the same time (coinfection) or HDV infection can occur in persons with chronic HBV (superinfection). Screening guidelines for HDV are inconsistent. While some guidelines recommend universal screening for all people with HBV, others recommend risk-based screening. Estimates of the global HDV prevalence range from 4.5 to 14.6% among persons with HBV; thus, there may be up to 72 million individuals with HDV worldwide. HDV is the most severe form of viral hepatitis. Compared to HBV monoinfection, HDV coinfection increases the risk of cirrhosis, hepatocellular carcinoma, hepatic decompensation, mortality, and necessity for liver transplant. Despite the severity of HDV, there are few treatment options. Pegylated interferon (off-label use) has long been the only available treatment, although bulevirtide is conditionally approved in some European countries. There are many potential treatments in development, but as yet, there are few effective and safe therapies for HDV infection. In conclusion, given the severity of HDV disease and the paucity of treatments, there is a great unmet need for HDV therapies.<\/jats:p>","DOI":"10.1055\/a-2133-8614","type":"journal-article","created":{"date-parts":[[2023,7,20]],"date-time":"2023-07-20T18:56:23Z","timestamp":1689879383000},"page":"293-304","source":"Crossref","is-referenced-by-count":24,"title":["Hepatitis Delta Infection: A Clinical Review"],"prefix":"10.1055","volume":"43","author":[{"given":"Brian","family":"Pearlman","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Wellstar Atlanta Medical Center, Medical College of Georgia, Emory School of Medicine, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2023,8,30]]},"reference":[{"issue":"01","key":"ref1","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/jmv.1890270107","article-title":"The size of the hepatitis delta agent","volume":"27","author":"L F He","year":"1989","journal-title":"J Med Virol"},{"issue":"10","key":"ref2","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1038\/nrgastro.2016.126","article-title":"Hepatitis delta virus: insights into a peculiar pathogen and novel treatment options","volume":"13","author":"F A Lempp","year":"2016","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"09","key":"ref3","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1136\/gutjnl-2020-323888","article-title":"Hepatitis D virus in 2021: virology, immunology and new treatment approaches for a difficult-to-treat disease","volume":"70","author":"S Urban","year":"2021","journal-title":"Gut"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"104812","DOI":"10.1016\/j.antiviral.2020.104812","article-title":"Current knowledge on hepatitis delta virus replication","volume":"179","author":"J Lucifora","year":"2020","journal-title":"Antiviral Res"},{"issue":"12","key":"ref5","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1136\/gut.18.12.997","article-title":"Immunofluorescence detection of new antigen-antibody system (delta\/anti-delta) associated to hepatitis B virus in liver and in serum of HBsAg carriers","volume":"18","author":"M Rizzetto","year":"1977","journal-title":"Gut"},{"issue":"03","key":"ref6","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.jhep.2020.02.030","article-title":"Chronic hepatitis D and hepatocellular carcinoma: a systematic review and meta-analysis of observational studies","volume":"73","author":"D Alfaiate","year":"2020","journal-title":"J Hepatol"},{"issue":"12","key":"ref7","doi-asserted-by":"crossref","first-page":"e115888","DOI":"10.1371\/journal.pone.0115888","article-title":"Epidemiological, clinical and histological characteristics of HBV\/HDV co-infection: a retrospective cross-sectional study in Guangdong, China","volume":"9","author":"B Liao","year":"2014","journal-title":"PLoS One"},{"issue":"05","key":"ref8","doi-asserted-by":"crossref","first-page":"100461","DOI":"10.1016\/j.jhepr.2022.100461","article-title":"Molecular epidemiology and clinical characteristics of hepatitis D virus infection in Canada","volume":"4","author":"C Osiowy","year":"2022","journal-title":"JHEP Rep Innov Hepatol"},{"issue":"03","key":"ref9","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1136\/gutjnl-2018-316601","article-title":"Prevalence and burden of hepatitis D virus infection in the global population: a systematic review and meta-analysis","volume":"68","author":"H Y Chen","year":"2019","journal-title":"Gut"},{"issue":"05","key":"ref10","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1053\/j.gastro.2009.01.052","article-title":"A 28-year study of the course of hepatitis delta infection: a risk factor for cirrhosis and hepatocellular carcinoma","volume":"136","author":"R Romeo","year":"2009","journal-title":"Gastroenterology"},{"issue":"03","key":"ref11","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.jhep.2020.04.008","article-title":"The global prevalence of hepatitis D virus infection: systematic review and meta-analysis","volume":"73","author":"A J Stockdale","year":"2020","journal-title":"J Hepatol"},{"key":"ref12","volume-title":"Hepatitis D Fact Sheet","author":"World Health Organization (WHO)","year":"2022"},{"issue":"10","key":"ref13","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1093\/infdis\/jiz633","article-title":"Estimating the global prevalence, disease progression, and clinical outcome of hepatitis delta virus infection","volume":"221","author":"Z Miao","year":"2020","journal-title":"J Infect Dis"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1016\/S0140-6736(15)61412-X","article-title":"Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013","volume":"386","author":"A Schweitzer","year":"2015","journal-title":"Lancet"},{"key":"ref15","first-page":"S211","article-title":"Population adjusted prevalence of hepatitis delta virus in 16 countries","volume":"76","author":"D Razavi-Shearer","year":"2022","journal-title":"Hepatology"},{"issue":"03","key":"ref16","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.jhep.2015.04.025","article-title":"Delta hepatitis within the Veterans Affairs medical system in the United States: prevalence, risk factors, and outcomes","volume":"63","author":"T Kushner","year":"2015","journal-title":"J Hepatol"},{"issue":"04","key":"ref17","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1093\/cid\/ciz001","article-title":"Prevalence of hepatitis B and hepatitis D virus infections in the United States, 2011-2016","volume":"69","author":"E U Patel","year":"2019","journal-title":"Clin Infect Dis"},{"issue":"02","key":"ref18","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1002\/hep.28279","article-title":"Prevalence of hepatitis delta infection in the United States: National Health and Nutrition Examination Survey, 1999-2012","volume":"64","author":"B Njei","year":"2016","journal-title":"Hepatology"},{"issue":"01","key":"ref19","doi-asserted-by":"crossref","first-page":"206","DOI":"10.14309\/ajg.0000000000000954","article-title":"Risk factors for delta hepatitis in a North American cohort: who should be screened?","volume":"116","author":"B L Da","year":"2021","journal-title":"Am J Gastroenterol"},{"issue":"04","key":"ref20","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"N A Terrault","year":"2018","journal-title":"Hepatology"},{"issue":"04","key":"ref21","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1093\/gastro\/goz023","article-title":"Hepatitis D infection: from initial discovery to current investigational therapies","volume":"7","author":"B L Da","year":"2019","journal-title":"Gastroenterol Rep (Oxf)"},{"issue":"S 01","key":"ref22","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/liv.14833","article-title":"Is hepatitis delta underestimated?","volume":"41","author":"M Papatheodoridi","year":"2021","journal-title":"Liver Int"},{"key":"ref23","first-page":"148A","article-title":"Low adherence to guidelines recommendation for testing hepatitis D in HBsAg positive patients leads to a high rate of undiagnosis","volume":"74","author":"A Palom","year":"2021","journal-title":"Hepatol"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.virusres.2018.03.013","article-title":"Hepatitis D diagnostics: utilization and testing in the United States","volume":"250","author":"P Safaie","year":"2018","journal-title":"Virus Res"},{"issue":"02","key":"ref25","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection","volume":"67","author":"European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu","year":"2017","journal-title":"J Hepatol"},{"issue":"01","key":"ref26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12072-015-9675-4","article-title":"Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update","volume":"10","author":"S K Sarin","year":"2016","journal-title":"Hepatol Int"},{"issue":"01","key":"ref27","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/nrgastro.2009.205","article-title":"Epidemiology, pathogenesis and management of hepatitis D: update and challenges ahead","volume":"7","author":"H Wedemeyer","year":"2010","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"03","key":"ref28","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1136\/gutjnl-2018-317403","article-title":"Devil hepatitis D: an orphan disease or largely underdiagnosed?","volume":"68","author":"H Wedemeyer","year":"2019","journal-title":"Gut"},{"issue":"05","key":"ref29","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/j.jhep.2020.05.019","article-title":"Revisiting the estimation of hepatitis D global prevalence","volume":"73","author":"Z Miao","year":"2020","journal-title":"J Hepatol"},{"issue":"02","key":"ref30","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1136\/gutjnl-2018-317874","article-title":"Hepatitis D prevalence: problems with extrapolation to global population estimates","volume":"69","author":"A J Stockdale","year":"2020","journal-title":"Gut"},{"issue":"04","key":"ref31","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1111\/j.1478-3231.2008.01673.x","article-title":"Seropositivity for delta hepatitis in patients with chronic hepatitis B and liver cirrhosis in Turkey: a meta-analysis","volume":"28","author":"H De\u011fertekin","year":"2008","journal-title":"Liver Int"},{"issue":"08","key":"ref32","doi-asserted-by":"crossref","first-page":"2833","DOI":"10.1007\/s10620-020-06499-6","article-title":"High prevalence of chronic viral hepatitis and liver fibrosis among Mongols in Southern California","volume":"66","author":"T L Fong","year":"2021","journal-title":"Dig Dis Sci"},{"issue":"06","key":"ref33","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1002\/hep.29574","article-title":"Genetic diversity and worldwide distribution of the delta virus genus: a study of 2,152 clinical strains","volume":"66","author":"F Le Gal","year":"2017","journal-title":"Hepatology"},{"issue":"06","key":"ref34","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1053\/j.gastro.2006.01.035","article-title":"Genotypes and viremia of hepatitis B and D viruses are associated with outcomes of chronic hepatitis D patients","volume":"130","author":"C W Su","year":"2006","journal-title":"Gastroenterology"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1099\/vir.0.013615-0","article-title":"Hepatitis B virus and hepatitis delta virus genotypes in outbreaks of fulminant hepatitis (Labrea black fever) in the western Brazilian Amazon region","volume":"90","author":"M S Gomes-Gouv\u00eaa","year":"2009","journal-title":"J Gen Virol"},{"issue":"06","key":"ref36","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1002\/jmv.25411","article-title":"Non-F HBV\/HDV-3 coinfection is associated with severe liver disease in Western Brazilian Amazon","volume":"91","author":"E Melo Da Silva","year":"2019","journal-title":"J Med Virol"},{"issue":"9785","key":"ref37","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0140-6736(10)61931-9","article-title":"Hepatitis delta virus","volume":"378","author":"S A Hughes","year":"2011","journal-title":"Lancet"},{"issue":"42","key":"ref38","doi-asserted-by":"crossref","first-page":"7271","DOI":"10.3748\/wjg.v27.i42.7271","article-title":"Hepatitis B virus\/hepatitis D virus epidemiology: changes over time and possible future influence of the SARS-CoV-2 pandemic","volume":"27","author":"C Sagnelli","year":"2021","journal-title":"World J Gastroenterol"},{"issue":"22","key":"ref39","doi-asserted-by":"crossref","first-page":"8774","DOI":"10.1073\/pnas.83.22.8774","article-title":"Structure and replication of the genome of the hepatitis delta virus","volume":"83","author":"P J Chen","year":"1986","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6088","key":"ref40","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/323558a0","article-title":"The hepatitis delta (delta) virus possesses a circular RNA","volume":"323","author":"A Kos","year":"1986","journal-title":"Nature"},{"issue":"6088","key":"ref41","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1038\/323508a0","article-title":"Structure, sequence and expression of the hepatitis delta (delta) viral genome","volume":"323","author":"K S Wang","year":"1986","journal-title":"Nature"},{"issue":"12","key":"ref42","doi-asserted-by":"crossref","first-page":"666","DOI":"10.4254\/wjh.v5.i12.666","article-title":"Life cycle and pathogenesis of hepatitis D virus: a review","volume":"5","author":"Z Abbas","year":"2013","journal-title":"World J Hepatol"},{"issue":"19","key":"ref43","doi-asserted-by":"crossref","first-page":"8490","DOI":"10.1073\/pnas.88.19.8490","article-title":"The large form of hepatitis delta antigen is crucial for assembly of hepatitis delta virus","volume":"88","author":"F L Chang","year":"1991","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"10","key":"ref44","doi-asserted-by":"crossref","first-page":"5066","DOI":"10.1128\/jvi.64.10.5066-5069.1990","article-title":"Role of two forms of hepatitis delta virus antigen: evidence for a mechanism of self-limiting genome replication","volume":"64","author":"M Chao","year":"1990","journal-title":"J Virol"},{"issue":"07","key":"ref45","doi-asserted-by":"crossref","first-page":"3192","DOI":"10.1128\/jvi.64.7.3192-3198.1990","article-title":"Hepatitis delta virus genome replication: a polyadenylated mRNA for delta antigen","volume":"64","author":"S Y Hsieh","year":"1990","journal-title":"J Virol"},{"issue":"05","key":"ref46","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1128\/jvi.63.5.1945-1950.1989","article-title":"Initiation of replication of the human hepatitis delta virus genome from cloned DNA: role of delta antigen","volume":"63","author":"M Y Kuo","year":"1989","journal-title":"J Virol"},{"key":"ref47","first-page":"123","article-title":"Control of ADAR1 editing of hepatitis delta virus RNAs","volume":"353","author":"J L Casey","year":"2012","journal-title":"Curr Top Microbiol Immunol"},{"issue":"12","key":"ref48","doi-asserted-by":"crossref","first-page":"7593","DOI":"10.1128\/jvi.69.12.7593-7600.1995","article-title":"Hepatitis D virus RNA editing: specific modification of adenosine in the antigenomic RNA","volume":"69","author":"J L Casey","year":"1995","journal-title":"J Virol"},{"issue":"15","key":"ref49","doi-asserted-by":"crossref","first-page":"8120","DOI":"10.1128\/JVI.78.15.8120-8134.2004","article-title":"By inhibiting replication, the large hepatitis delta antigen can indirectly regulate amber\/W editing and its own expression","volume":"78","author":"S Sato","year":"2004","journal-title":"J Virol"},{"issue":"18","key":"ref50","doi-asserted-by":"crossref","first-page":"8547","DOI":"10.1128\/JVI.75.18.8547-8555.2001","article-title":"Hepatitis delta virus minimal substrates competent for editing by ADAR1 and ADAR2","volume":"75","author":"S Sato","year":"2001","journal-title":"J Virol"},{"issue":"23","key":"ref51","doi-asserted-by":"crossref","first-page":"15118","DOI":"10.1073\/pnas.232416799","article-title":"Replicating hepatitis delta virus RNA is edited in the nucleus by the small form of ADAR1","volume":"99","author":"S K Wong","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5061","key":"ref52","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1126\/science.1598578","article-title":"Identification of a prenylation site in delta virus large antigen","volume":"256","author":"J S Glenn","year":"1992","journal-title":"Science"},{"issue":"01","key":"ref53","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1006\/viro.1994.1109","article-title":"Isoprenylation of large hepatitis delta antigen is necessary but not sufficient for hepatitis delta virus assembly","volume":"199","author":"C Z Lee","year":"1994","journal-title":"Virology"},{"issue":"03","key":"ref54","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/j.jhep.2020.11.032","article-title":"New insights into HDV persistence: the role of interferon response and implications for upcoming novel therapies","volume":"74","author":"Z Zhang","year":"2021","journal-title":"J Hepatol"},{"issue":"28","key":"ref55","doi-asserted-by":"crossref","first-page":"e26571","DOI":"10.1097\/MD.0000000000026571","article-title":"Poor clinical and virological outcome of nucleos(t)ide analogue monotherapy in HBV\/HDV co-infected patients","volume":"100","author":"L Scheller","year":"2021","journal-title":"Medicine (Baltimore)"},{"issue":"07","key":"ref56","doi-asserted-by":"crossref","first-page":"a021576","DOI":"10.1101\/cshperspect.a021576","article-title":"Hepatitis D virus: introduction and epidemiology","volume":"5","author":"M Rizzetto","year":"2015","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"04","key":"ref57","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1111\/liv.13556","article-title":"Hepatitis B virus-hepatitis D virus mother-to-child co-transmission: a retrospective study in a developed country","volume":"38","author":"P O Sellier","year":"2018","journal-title":"Liver Int"},{"issue":"11","key":"ref58","doi-asserted-by":"crossref","first-page":"a021550","DOI":"10.1101\/cshperspect.a021550","article-title":"Hepatitis D virus coinfection and superinfection","volume":"4","author":"F Negro","year":"2014","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"02","key":"ref59","first-page":"221","article-title":"Hepatitis D: virology, clinical and epidemiological aspects","volume":"63","author":"M Rizzetto","year":"2000","journal-title":"Acta Gastroenterol Belg"},{"issue":"12","key":"ref60","doi-asserted-by":"crossref","first-page":"3587","DOI":"10.1007\/s00705-017-3538-3","article-title":"The serological markers of acute infection with hepatitis A, B, C, D, E and G viruses revisited","volume":"162","author":"R AA Pond\u00e9","year":"2017","journal-title":"Arch Virol"},{"issue":"03","key":"ref61","doi-asserted-by":"crossref","first-page":"291","DOI":"10.4254\/wjh.v13.i3.291","article-title":"Hepatitis D virus and liver transplantation: indications and outcomes","volume":"13","author":"H Muhammad","year":"2021","journal-title":"World J Hepatol"},{"issue":"05","key":"ref62","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.jhep.2010.06.008","article-title":"Outcome of chronic delta hepatitis in Italy: a long-term cohort study","volume":"53","author":"G A Niro","year":"2010","journal-title":"J Hepatol"},{"issue":"02","key":"ref63","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1111\/liv.13205","article-title":"Non-invasive fibrosis score for hepatitis delta","volume":"37","author":"G L Lutterkort","year":"2017","journal-title":"Liver Int"},{"issue":"11","key":"ref64","doi-asserted-by":"crossref","first-page":"e154","DOI":"10.1111\/jvh.12251","article-title":"Development and evaluation of a baseline-event-anticipation score for hepatitis delta","volume":"21","author":"B Calle Serrano","year":"2014","journal-title":"J Viral Hepat"},{"issue":"01","key":"ref65","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/apt.15521","article-title":"Long-term clinical outcomes in patients with chronic hepatitis delta: the role of persistent viraemia","volume":"51","author":"A Palom","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"issue":"04","key":"ref66","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1111\/apt.16485","article-title":"One-quarter of chronic hepatitis D patients reach HDV-RNA decline or undetectability during the natural course of the disease","volume":"54","author":"A Palom","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"key":"ref67","doi-asserted-by":"publisher","DOI":"10.1111\/liv.15467","article-title":"Natural history of untreated HDV patients: always a progressive disease?","author":"H Kamal","year":"2022","journal-title":"Liver Int"},{"issue":"04","key":"ref68","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1002\/hep.31214","article-title":"Long-term study of hepatitis delta virus Infection at secondary care centers: the impact of viremia on liver-related outcomes","volume":"72","author":"H Kamal","year":"2020","journal-title":"Hepatology"},{"issue":"03","key":"ref69","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.cld.2020.04.008","article-title":"Viral hepatitis other than A, B, and C: evaluation and management","volume":"24","author":"A Cheung","year":"2020","journal-title":"Clin Liver Dis"},{"issue":"01","key":"ref70","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s13099-021-00462-0","article-title":"Hepatitis D: challenges in the estimation of true prevalence and laboratory diagnosis","volume":"13","author":"L Y Chen","year":"2021","journal-title":"Gut Pathog"},{"issue":"03","key":"ref71","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1055\/s-0032-1323627","article-title":"Hepatitis delta virus diagnosis","volume":"32","author":"A Olivero","year":"2012","journal-title":"Semin Liver Dis"},{"issue":"07","key":"ref72","doi-asserted-by":"crossref","first-page":"e101002","DOI":"10.1371\/journal.pone.0101002","article-title":"Anti-HDV IgM as a marker of disease activity in hepatitis delta","volume":"9","author":"A Wranke","year":"2014","journal-title":"PLoS One"},{"issue":"03","key":"ref73","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1111\/j.1478-3231.2009.02140.x","article-title":"Quantitative HBsAg and HDV-RNA levels in chronic delta hepatitis","volume":"30","author":"K Zachou","year":"2010","journal-title":"Liver Int"},{"issue":"08","key":"ref74","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1007\/s00330-009-1313-x","article-title":"Liver fibrosis staging with contrast-enhanced ultrasonography: prospective multicenter study compared with METAVIR scoring","volume":"19","author":"F Staub","year":"2009","journal-title":"Eur Radiol"},{"issue":"07","key":"ref75","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJM200102153440706","article-title":"Liver biopsy","volume":"344","author":"A A Bravo","year":"2001","journal-title":"N Engl J Med"},{"issue":"01","key":"ref76","doi-asserted-by":"crossref","first-page":"169","DOI":"10.4269\/ajtmh.19-0688","article-title":"Noninvasive models for predicting liver fibrosis in individuals with hepatitis D virus\/hepatitis B virus coinfection in the Brazilian Amazon region","volume":"103","author":"M P Alves Vasconcelos","year":"2020","journal-title":"Am J Trop Med Hyg"},{"issue":"04","key":"ref77","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1111\/jvh.13235","article-title":"Vibration-controlled transient elastography for the detection of cirrhosis in chronic hepatitis D infection","volume":"27","author":"B L Da","year":"2020","journal-title":"J Viral Hepat"},{"issue":"01","key":"ref78","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1111\/apt.13834","article-title":"Noninvasive markers for staging fibrosis in chronic delta hepatitis","volume":"45","author":"V Takyar","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"issue":"05","key":"ref79","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1111\/jvh.13806","article-title":"Non-invasive fibrosis markers for assessment of liver fibrosis in chronic hepatitis delta","volume":"30","author":"\u00c7 Kalkan","year":"2023","journal-title":"J Viral Hepat"},{"issue":"03","key":"ref80","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"H Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"02","key":"ref81","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.jhepr.2019.05.001","article-title":"The oncogenic role of hepatitis delta virus in hepatocellular carcinoma","volume":"1","author":"M Puigveh\u00ed","year":"2019","journal-title":"JHEP Rep Innov Hepatol"},{"issue":"S 01","key":"ref82","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/liv.14356","article-title":"Future treatments for hepatitis delta virus infection","volume":"40","author":"T Asselah","year":"2020","journal-title":"Liver Int"},{"issue":"05","key":"ref83","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/j.jhep.2018.12.022","article-title":"Treating chronic hepatitis delta: the need for surrogate markers of treatment efficacy","volume":"70","author":"C Yurdaydin","year":"2019","journal-title":"J Hepatol"},{"issue":"03","key":"ref84","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1002\/hep.21296","article-title":"Pegylated interferon alpha-2b as monotherapy or in combination with ribavirin in chronic hepatitis delta","volume":"44","author":"G A Niro","year":"2006","journal-title":"Hepatology"},{"issue":"01","key":"ref85","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1002\/hep.27102","article-title":"Late HDV RNA relapse after peginterferon alpha-based therapy of chronic hepatitis delta","volume":"60","author":"B Heidrich","year":"2014","journal-title":"Hepatology"},{"issue":"06","key":"ref86","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1097\/HEP.0000000000000309","article-title":"Treatment of chronic hepatitis D with peginterferon lambda-the phase 2 LIMT-1 clinical trial","volume":"77","author":"O Etzion","year":"2023","journal-title":"Hepatology"},{"issue":"01","key":"ref89","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S1473-3099(22)00318-8","article-title":"Safety and efficacy of bulevirtide in combination with tenofovir disoproxil fumarate in patients with hepatitis B virus and hepatitis D virus coinfection (MYR202): a multicentre, randomised, parallel-group, open-label, phase 2 trial","volume":"23","author":"H Wedemeyer","year":"2023","journal-title":"Lancet Infect Dis"},{"key":"ref90","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1016\/S0168-8278(22)00433-0","article-title":"Efficacy and safety of bulevirtide monotherapy given at 2\u2009mg or 10\u2009mg dose level once daily OFR treatment of chronic hepatitis delta: week 48 primary end point results from a phase 3 randomized, multicenter, parallel design study","volume":"77","author":"H Wedemeyer","year":"2022","journal-title":"J Hepatol"},{"key":"ref91","first-page":"S26","article-title":"Bulevirtide, with or without peg-interferon, in HDV infected patients in a real-life setting, two-year results from the French multicenter early access program","volume":"76","author":"V De Ledinghen","year":"2022","journal-title":"Hepatol"},{"key":"ref92","volume-title":"Anonymous. Hepcludex. Summary of Product Characteristics. Carrigtwohill, County Cork: Gilead Sciences Ireland UC","year":"2021"},{"issue":"10","key":"ref93","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/S1473-3099(15)00074-2","article-title":"Oral prenylation inhibition with lonafarnib in chronic hepatitis D infection: a proof-of-concept randomised, double-blind, placebo-controlled phase 2A trial","volume":"15","author":"C Koh","year":"2015","journal-title":"Lancet Infect Dis"},{"issue":"06","key":"ref94","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1002\/hep.32259","article-title":"A phase 2 dose-finding study of lonafarnib and ritonavir with or without interferon alpha for chronic delta hepatitis","volume":"75","author":"C Yurdaydin","year":"2022","journal-title":"Hepatology"},{"issue":"12","key":"ref95","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/S2468-1253(17)30288-1","article-title":"Safety and efficacy of REP 2139 and pegylated interferon alfa-2a for treatment-naive patients with chronic hepatitis B virus and hepatitis D virus co-infection (REP 301 and REP 301-LTF): a non-randomised, open-label, phase 2 trial","volume":"2","author":"M Bazinet","year":"2017","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"02","key":"ref96","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1002\/hep4.1633","article-title":"Persistent control of hepatitis B virus and hepatitis delta virus infection following REP 2139-Ca and pegylated interferon therapy in chronic hepatitis B virus\/hepatitis delta virus coinfection","volume":"5","author":"M Bazinet","year":"2020","journal-title":"Hepatol Commun"},{"issue":"06","key":"ref97","doi-asserted-by":"crossref","first-page":"3479","DOI":"10.1002\/hep.32082","article-title":"Endpoints and new options for treatment of chronic hepatitis D","volume":"74","author":"A S Lok","year":"2021","journal-title":"Hepatology"},{"key":"ref98","doi-asserted-by":"crossref","first-page":"461","DOI":"10.2147\/JEP.S235550","article-title":"Experimental drugs for the treatment of hepatitis D","volume":"13","author":"L Sandmann","year":"2021","journal-title":"J Exp Pharmacol"}],"container-title":["Seminars in Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2133-8614.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T19:36:41Z","timestamp":1698867401000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2133-8614"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,20]]},"references-count":96,"journal-issue":{"issue":"03","published-online":{"date-parts":[[2023,11,1]]},"published-print":{"date-parts":[[2023,8]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2133-8614","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0272-8087","1098-8971"],"issn-type":[{"value":"0272-8087","type":"print"},{"value":"1098-8971","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,7,20]]},"published":{"date-parts":[[2023,7,20]]}}}